Subscribe To

Price Alert Latest News Economic Calendar News

ACAD / ACADIA Pharmaceuticals Inc. (ACAD) Q4 2022 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President, Investor Relations Steve Davis - Chief Executive Officer Mark Schneyer - Chief Financial Officer Brendan Teehan - Chief Operating Officer, Head, Commercial Kathie Bishop - Chief Scientific Officer and Head, Rare Disease Doug Williamson - Head, Research and Development Conference Call Participants Ritu Baral - Cowen Tessa Romero - J.P. Morgan Marc Goodman - SVB Leerink Tazeen Ahmad - Bank of America Merrill Lynch Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Eddie Hickman - Guggenheim Partners Gregory Renza - RBC Capital Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer David Hoang - SMBC Nikko Kyle Qian - Canaccord Genuity Operator Good day, ladies and gentlemen. Read More

Demo Live Account See Partner Details

Content Topics

Acadia

Pharmaceuticals

Inc

ACAD

2022

Earnings

Call

acad

Transcript

Stock

Posted: Feb 27 2023, 22:12

Author Name: Seeking Alpha

ACAD News

By Zacks Investment Research
November 3, 2023

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours

By Seeking Alpha
November 3, 2023

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2023 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associa

By Zacks Investment Research
October 12, 2023

Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

By The Motley Fool
September 30, 2023

2 Growth Stocks I'd Buy on the Dip

September hasn't been overly kind to growth stocks. This latest bout of volatility, however, may have created some compelling buying opportunities.

By Zacks Investment Research
September 28, 2023

Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions

By Invezz
September 27, 2023

Acadia stock price analysis: ACAD risk/reward is attractive

Acadia Pharmaceuticals (NASDAQ: ACAD) stock price did well on Wednesday even as American equities retreated. The biotech stock jumped to a high of $26

By Seeking Alpha
September 26, 2023

Acadia Pharmaceuticals: Difficult Market Masks Progress

Acadia Pharmaceuticals' gains recently disappeared despite the strong launch of Daybue. Poor market conditions are to blame, especially the poor biote

By Seeking Alpha
September 23, 2023

Daybue Drives Acadia Pharmaceuticals To Positive Earnings (Rating Upgrade)

Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by Daybue's strong Q2 debut and increased Nuplazid sales. D

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.